



PR Newswire on Yahoo

[ARCHIVE](#)

Gilad&Gilad Successfully Defends Agmatine Patents

LOS ANGELES, Jan. 26, 2016 /PRNewswire/ – [Gilad&Gilad](#) has reached an out-of-court settlement following issuance of a Cease and Desist Letter against a South Florida company for alleged infringements of its agmatine patents on nerve health.

Logo - <http://photos.prnewswire.com/prnh/20160125/325778LOGO>

Gilad&Gilad LLC has recently served a Cease and Desist Letter to a South Florida dietary supplement marketer for alleged patent infringements upon Gilad&Gilad's patents covering methods of agmatine usage. The alleged infringing company chose to avoid legal litigation and settled out of court. The financial terms of the settlement are confidential; however, in conjunction with the settlement the South Florida Company agreed to cease promoting agmatine products for nerve health and for brain health indications.

"As the discoverers of the neuroprotective properties of agmatine and the pioneers in introducing agmatine-containing products for nerve health into commerce, we are very pleased to see the increased recognition of the enormous potential of agmatine and, concomitantly, the continuously expanding use of our products," notes Dr. Gad M. Gilad, Gilad&Gilad's CEO. "There is an unmet need for a safe and effective supplement by millions who are coping everyday with great challenges to their nervous system health and with threats to maintaining resilient pain-free nerve functions."

Because of their discoveries, Gilad&Gilad's scientists were granted patents nos. 5,677,349 and 8,916,612 B2 for the use of agmatine to support healthy nerve functions and for its use at high dosages in dietary supplements, nutraceuticals and foods. The issuance of these patents has been publicly announced in recent press releases by Gilad&Gilad and is indicated on Gilad&Gilad's website, www.ForNerveHealth.com.

"As a business entity, the patents grant us a unique market position and provide protection to our discoveries and investments against infringements. We have invested enormous amount of resources and efforts in product development including scientific, clinical, safety and toxicity studies, as well as in ongoing clinical trials," Dr. Gilad emphasizes. "Thus far, we have not licensed our intellectual property to anyone. Gilad&Gilad will continue to watch for infringements and will undertake whatever legal action necessary to protect our property."

"As for now, aside from supporting and maintaining nerve health, there are no additional indications for agmatine usage which are backed by clinical studies," Dr. Gilad points out. "Companies which are promoting agmatine for any indications other than nerve health are deceiving their customers. Moreover, that agmatine is touted for bodybuilding, is completely unsubstantiated and is backed by outright false claims. The scores of companies now selling agmatine-containing products for bodybuilding are frankly deceiving and callous. These companies dupe customers and directly damage the reputation of the dietary supplement industry."

Gilad&Gilad has developed the exclusive For-Nerve-Health™ product line and markets the first-of-kind products, AgmaSet® and AgmaVet™, which contain G-Agmatine® (Gilad&Gilad's proprietary brand of agmatine).

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

About Gilad&Gilad

[Gilad&Gilad LLC](#) is a privately owned, health science company with unique competency in Neuroscience. The principal mission of the company is to provide evidence-based safe and effective products of superior quality for healthier nervous system functions. The Company was founded by Dr. Gad M. Gilad and Ms. Varda H. Gilad following years of collaborative scientific research and based on their breakthrough discovery of the neuroprotective properties of G-Agmatine®, Gilad&Gilad's proprietary brand of agmatine. The Company has developed the exclusive For-Nerve-Health™ product line and markets the first-of-kind products, AgmaSet® and AgmaVet™. The Company builds its reputation by continuous investment in high standard scientific research and

clinical studies, thus earning the trust of healthcare professionals and gaining credibility with the public. - For further information about Gilad&Gilad please visit www.ForNerveHealth.com.

Contact:

Gad M. Gilad, Ph.D.
CEO, Gilad&Gilad LLC
19020 Kittridge St., Unit 1, Reseda, CA 91335
Tel: 323-599-0774; Tel/Fax: 818-708-8505
Email: gmg@GiladandGilad.com; www.ForNerveHealth.com

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/giladgilad-successfully-defends-agmatine-patents-300209603.html>

[Source: prnewswire.com](http://prnewswire.com)

[Jan 26th, 2016](#)

MORE YOU MIGHT LIKE